CRMD CorMedix Inc

1.4
-0.06  -4%
Previous Close 1.46
Open 1.47
Price To Book -15.56
Market Cap 147434560
Shares 105,310,400
Volume 1,229,721
Short Ratio 5.28
Av. Daily Volume 3,998,989

SEC filingsSee all SEC filings

  1. 8-K - Current report 181229055
  2. 8-K - Current report 181226653
  3. 424B5 - Prospectus [Rule 424(b)(5)] 181187878
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181184773
  5. 8-K - Current report 181184135

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 interim analysis July 25, 2018 by DSMB recommended trial to be stopped early as sufficient efficacy has been demonstrated.
Neutrolin - LOCK-IT 100
Hemodialysis patients with central venous catheters
Phase 3 to be initiated pending funding.
Neutrolin - LOCK-IT 200
Oncology patients on Total Parental Nutrition (TPN)

Latest News

  1. CBD and Biotech Plays on The Rise
  2. Cormedix Receives Approval to Sell $5.4 Million of NOL Tax Benefits Through the New Jersey Economic Development Authority Program
  3. Biomedical Trends Fuel New Momentum For Healthcare Stocks; Premier Health Group, Inc. (OTC: PHGRF) (CSE: PHGI), Alliqua BioMedical, BioScrip, Coremedix
  4. Consolidated Research: 2018 Summary Expectations for Kadmon, Overstock, AECOM, Steelcase, CorMedix, and Corindus Vascular Robotics — Fundamental Analysis, Key Performance Indications
  5. CBD and Biotech Stocks to Watch
  6. CorMedix: 3Q Earnings Snapshot
  7. CorMedix Inc. Reports Third Quarter Financial Results and Provides Business Update
  8. CorMedix Inc. to Report Third Quarter 2018 Financial Results on Wednesday, November 14
  9. 3 Healthcare Stocks Using Technology To Boost Growth
  10. Penny Stocks to Buy Using Technical Analysis for November 2018
  11. Recent Analysis Shows Lantheus, Editas Medicine, CorMedix, DXP Enterprises, Peabody Energy, and CommScope Holding Market Influences — Renewed Outlook, Key Drivers of Growth
  12. CorMedix Inc. Clarifies That No New Shares Are Being Issued In Connection With Its Recently Filed Form S-3 Registration Statement
  13. What Kind Of Shareholders Own CorMedix Inc (NYSEMKT:CRMD)?
  14. CorMedix Announces NYSE American Acceptance of Plan to Regain Listing Compliance
  15. CorMedix Inc. to Present at The 20th Annual Rodman & Renshaw Global Investment Conference
  16. CorMedix Inc. Reports Second Quarter Financial Results and Provides Business Update
  17. CorMedix Inc. to Host Earnings Call
  18. CorMedix Inc. to Report Second Quarter 2018 Financial Results on Tuesday, August 14

SEC Filings

  1. 8-K - Current report 181229055
  2. 8-K - Current report 181226653
  3. 424B5 - Prospectus [Rule 424(b)(5)] 181187878
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181184773
  5. 8-K - Current report 181184135
  6. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 181154641
  7. DEF 14A - Other definitive proxy statements 181154627
  8. EFFECT - Notice of Effectiveness 181135189
  9. 424B3 - Prospectus [Rule 424(b)(3)] 181134569
  10. UPLOAD [Cover] - SEC-generated letter